埃塞俄比亚2015-2024年麻疹与疫苗接种的时空趋势
该研究分析埃塞俄比亚2015-2024年麻疹监测数据及疫苗接种数据,评估第二剂麻疹疫苗(MCV2)引入后的影响。十年间共报告95,904例麻疹病例,发病率在2021年后急剧上升并于2024年达峰;MCV2引入后发病率未见显著变化。
要点
- 2015-2024年埃塞俄比亚报告95,904例麻疹,2021年后发病率急剧上升,2024年达峰。
- 五岁以下儿童约占半数病例,热点地区随时间变化。
- MCV2引入后发病率无显著变化,首剂覆盖率从56%升至72%,第二剂从35%升至59%。
核心结论
- 麻疹仍是埃塞俄比亚重大公共卫生挑战,近年发病率上升且地理差异显著。
- 尽管常规免疫改善,覆盖率仍低于消除所需水平,MCV2引入尚未产生可测量影响。
研究设计与样本
- 分析2015-2024年埃塞俄比亚公共卫生应急管理系统麻疹监测数据。
- 疫苗接种数据来自WHO/UNICEF估计及2016和2019年人口与健康调查。
- 采用中断时间序列分析评估2019年MCV2引入后发病率变化。
主要发现
- 2015-2024年共报告95,904例麻疹病例,高峰出现在2015、2023和2024年。
- 五岁以下儿童约占半数病例,发病率在西部、西南部和南部地区最高,热点随时间变化。
- 全国发病率至2021年下降,随后急剧上升,2024年达峰;多数病例发生于干燥冬季。
- 首剂疫苗接种覆盖率从2015年56%升至2024年72%,第二剂从2019年引入时35%升至2024年59%。
- 中断时间序列分析未发现MCV2引入后发病率有显著变化。
临床怎么用
- 需加强常规疫苗接种以缩小免疫缺口。
- 提升监测质量并针对服务不足地区精准干预。
- 关注五岁以下儿童及冬季高发时段的防控。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Measles is a leading vaccine-preventable cause of child morbidity and mortality, with Ethiopia's recent resurgence driven by suboptimal vaccination coverage and repeated crises. This highlights the need to close immunity gaps in line with the WHO Immunisation Agenda 2030 (IA2030). We analysed national and subnational measles and vaccination patterns to provide timely evidence to guide progress. METHODS: We analysed 2015-2024 measles surveillance data from the Ethiopian Public Health Emergency Management system. Vaccination data was obtained from WHO/UNICEF estimates and subnational vaccination data from 2016 and 2019 Demographic and Health Surveys. We analysed demographic, temporal, and spatial patterns of measles and measles vaccination. An interrupted time-series analysis assessed changes in incidence following the introduction of the second routine measles dose (MCV2) in 2019. RESULTS: Between 2015 and 2024, Ethiopia reported 95,904 measles cases, with substantial variation and peaks in 2015, 2023, and 2024. Children under five accounted for about half cases, and incidence was highest in western, south-western, and southern regions, with shifting hotspots over time. National incidence declined until 2021, then rose sharply, reaching its peak in 2024. Most cases occurred in dry winter season. First-dose vaccination coverage increased from 56% in 2015 to 72% in 2024, while second-dose coverage rose from 35% at its 2019 introduction to 59% in 2024. Our analysis found no significant change in incidence following the introduction of MCV2. CONCLUSION: Measles remains a major public health challenge in Ethiopia, with rising incidence in recent years and marked geographic disparities in disease burden and vaccination coverage. Despite improvements in routine immunisation, coverage remains below levels required for elimination, and the introduction of MCV2 has not yet produced a measurable impact. Strengthening routine vaccination, enhancing surveillance quality, and targeting underserved regions are essential to reduce measles transmission and move towards national and global elimination goals.
引用
- Yitbarek K, Sheel M, Woldie M, et al. Spatial and temporal trends of measles and measles vaccination status in Ethiopia, 2015-2024. Vaccine. 2026. PMID: 41905063. doi:10.1016/j.vaccine.2026.128524
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。